On Monday, Fate Therapeutics Inc (NASDAQ: FATE) was -14.98% drop from the session before settling in for the closing price of $1.63. A 52-week range for FATE has been $0.66 – $3.50.
A company in the Healthcare sector has dropped its sales by -2.63% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 30.05%. With a float of $109.47 million, this company’s outstanding shares have now reached $114.66 million.
In an organization with 181 employees, it is important to assess its efficiency.
Fate Therapeutics Inc (FATE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Fate Therapeutics Inc stocks. The insider ownership of Fate Therapeutics Inc is 5.08%, while institutional ownership is 70.46%. The most recent insider transaction that took place on Aug 04 ’25, was worth 9,573. In this transaction an insider of this company sold 9,037 shares at a rate of $1.06, taking the stock ownership to the 397,670 shares. Before that another transaction happened on Aug 04 ’25, when Company’s President and CEO sold 14,466 for $1.06, making the entire transaction worth $15,396. This insider now owns 334,898 shares in total.
Fate Therapeutics Inc (FATE) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.4 earnings per share (EPS) during the time that was better than consensus figure (set at -0.41) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.70% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
You can see what Fate Therapeutics Inc (FATE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.10 in one year’s time.
